These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 32121)

  • 21. Hemodynamic effects of labetalol, an alpha and beta adrenergic blocking agent, in hypertensive subjects.
    Mehta J; Cohn JN
    Circulation; 1977 Feb; 55(2):370-5. PubMed ID: 12880
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of medroxalol and labetalol, drugs with combined alpha- and beta-adrenoceptor antagonist properties.
    Elliott HL; McLean K; Meredith PA; Sumner DJ; Reid JL
    Br J Clin Pharmacol; 1984 May; 17(5):565-72. PubMed ID: 6145440
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The pharmacological basis for the use of labetalol in the treatment of hypertension.
    Prichard BN; Richards DA
    J Cardiovasc Pharmacol; 1981; 3 Suppl 1():S24-9. PubMed ID: 6169957
    [No Abstract]   [Full Text] [Related]  

  • 24. Labetalol: an alpha- and beta-blocker.
    Conner CS
    Drug Intell Clin Pharm; 1983; 17(7-8):543-4. PubMed ID: 6135593
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alpha-adrenoceptor blockade by labetalol during long-term dosing.
    Semplicini A; Pessina AC; Rossi GP; Hlede M; Morandin F
    Clin Pharmacol Ther; 1983 Mar; 33(3):278-82. PubMed ID: 6130864
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Labetalol blockade of central alpha- and beta-noradrenergic receptors in rat brain homogenates.
    Devoto P; Stefanini E; Marchisio AM; Vernaleone F; Collu R
    Pharmacol Res Commun; 1980 Feb; 12(2):177-82. PubMed ID: 6104337
    [No Abstract]   [Full Text] [Related]  

  • 27. [Essential arterial hypertension. Effects of labetalol on blood pressure and renin-angiotensin system (author's transl)].
    Martinand A; Lardoux H; Corvol P; Milliez P
    Nouv Presse Med; 1980 Sep; 9(35):2565-8. PubMed ID: 7001349
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current status of labetalol, the first alpha- and beta-blocking agent.
    Kanto JH
    Int J Clin Pharmacol Ther Toxicol; 1985 Nov; 23(11):617-28. PubMed ID: 2867049
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined alpha- and beta-receptor inhibition in the treatment of hypertension.
    Prichard BN
    Drugs; 1984; 28 Suppl 2():51-68. PubMed ID: 6151891
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Labetalol in the treatment of severe essential hypertension: relationship between arterial blood pressure, plasma catecholamines, plasma renin activity, plasma aldosterone and body weight.
    Kornerup HJ; Pedersen EB; Christensen NJ; Pedersen A; Pedersen G
    Acta Med Scand Suppl; 1979; 625():59-64. PubMed ID: 34981
    [No Abstract]   [Full Text] [Related]  

  • 31. Closing remarks: current status of labetalol.
    Dollery CT
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):823-4. PubMed ID: 10954
    [No Abstract]   [Full Text] [Related]  

  • 32. Effects of the R, R-isomer of labetalol, SCH 19927, in isolated tissues and in spontaneously hypertensive rats during a repeated treatment.
    Monopoli A; Bamonte F; Forlani A; Ongini E; Parravicini L
    Arch Int Pharmacodyn Ther; 1984 Dec; 272(2):256-63. PubMed ID: 6151824
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alpha and beta adrenoceptor blocking properties of labetalol and its R,R-isomer, SCH 19927.
    Sybertz EJ; Sabin CS; Pula KK; Vliet GV; Glennon J; Gold EH; Baum T
    J Pharmacol Exp Ther; 1981 Aug; 218(2):435-43. PubMed ID: 6114171
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Labetolol--combined alpha and beta blockade for hypertension.
    Raftery EB
    Scott Med J; 1978 Oct; 23(4):279-80. PubMed ID: 31683
    [No Abstract]   [Full Text] [Related]  

  • 35. Sympathetic nervous activity and the pressor effect of noradrenaline under chronic alpha-beta-adrenoceptor blockade with labetalol in hypertension.
    Zschiedrich H; Neurohr W; Lüth JB; Philipp T; Distler A
    Klin Wochenschr; 1983 Jul; 61(13):661-7. PubMed ID: 6310204
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alpha- and beta-blocking activities of racemates of labetalol.
    Nakagawa Y; Shimamoto N; Nakazawa M; Imai S
    Jpn J Pharmacol; 1980 Oct; 30(5):743-5. PubMed ID: 6110798
    [No Abstract]   [Full Text] [Related]  

  • 37. Antihypertensive effect of labetalol, a new alpha- and beta-adrenergic blocking agent.
    Hansson L; Hänel B
    Int J Clin Pharmacol Biopharm; 1976 Oct; 14(3):195-8. PubMed ID: 12115
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hemodynamic changes after acute and long-term combined alpha--beta-adrenoceptor blockade with labetalol as compared with beta-receptor blockade.
    Koch G
    J Cardiovasc Pharmacol; 1981; 3 Suppl 1():S30-41. PubMed ID: 6169958
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Autonomic and antihypertensive activity of oral amosulalol (YM-09538), a combined alpha- and beta-adrenoceptor blocking agent in conscious rats.
    Honda K; Takenaka T; Shiono K; Miyata-Osawa A; Nakagawa C
    Jpn J Pharmacol; 1985 May; 38(1):31-41. PubMed ID: 2862302
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of labetalol on plasma noradrenaline and adrenaline in hypertensive man.
    Christensen NJ; Trap-Jensen J; Svendsen TL; Rasmussen S; Nielsen PE
    Eur J Clin Pharmacol; 1978 Dec; 14(4):227-30. PubMed ID: 365539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.